EMA starts rolling review of Janssen’s COVID-19 vaccine Ad26.COV2.S

EMA

1 December 2020 - EMA’s CHMP has started a rolling review of Ad26.COV2.S, a COVID-19 vaccine from Janssen-Cilag.

The CHMP’s decision to start the rolling review is based on preliminary results from laboratory studies and early clinical studies in adults.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Europe , Vaccine , Dossier , COVID-19